Skip to main content

DURECT Corporation (DRRX)

NASDAQ: DRRX · IEX Real-Time Price · USD
1.28
-0.01 (-0.78%)
After-hours:Sep 23, 2021 4:37 PM EDT
1.29
0.05 (4.03%)
At close: Sep 23, 4:00 PM
Market Cap282.10M
Revenue (ttm)6.01M
Net Income (ttm)-24.25M
Shares Out227.43M
EPS (ttm)-0.12
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume426,408
Open1.26
Previous Close1.24
Day's Range1.23 - 1.30
52-Week Range1.20 - 2.95
Beta1.25
AnalystsBuy
Price Target6.50 (+403.9%)
Est. Earnings DateNov 1, 2021

About DRRX

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops DUR-928, an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid homeostasis, inflammation, and cell survival, as well as completed Phase Ib clinical trial to treat patients ...

IndustryPharmaceuticals
IPO DateSep 28, 2000
CEOJames Brown
Employees79
Stock ExchangeNASDAQ
Ticker SymbolDRRX
Full Company Profile

Financial Performance

In 2020, DRRX's revenue was $30.11 million, an increase of 20.09% compared to the previous year's $25.07 million. Losses were -$582,000, -97.17% less than in 2019.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for DRRX stock is "Buy." The 12-month stock price forecast is 6.50, which is an increase of 403.88% from the latest price.

Price Target
$6.50
(403.88% upside)
Analyst Consensus: Buy

News

DURECT Corporation Fireside Chat at the Cantor Fitzgerald Global Healthcare Conference 2021

CUPERTINO, Calif., Sept. 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

18 hours ago - PRNewsWire

DURECT Corporation Fireside Chat at Oppenheimer's Fall Healthcare Life Sciences & MedTech Summit

CUPERTINO, Calif., Sept. 15, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E.

1 week ago - PRNewsWire

DURECT Corporation Fireside Chat at the H.C. Wainwright Annual Global Investment Conference

CUPERTINO, Calif., Sept. 7, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that James E.

2 weeks ago - PRNewsWire

Durect (DRRX) Reports Q2 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -16.56%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

DURECT Corporation Announces Second Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., July 29, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended June 30, 2021 and provided a corporate update.

1 month ago - PRNewsWire

DURECT Corporation to Announce Second Quarter 2021 Financial Results and Provide Business Update on July 29

CUPERTINO, Calif., July 22, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its second quarter 2021 financial results and host a conference call after the mark...

2 months ago - PRNewsWire

DURECT Corporation to Present at the 2021 Epigenetic Therapeutic Targets Virtual Summit

CUPERTINO, Calif., July 14, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present at the Epigenetic Therapeutic Targets Summit, being held virtually July 13-15, 2021.

2 months ago - PRNewsWire

DURECT Corporation Presents Additional Clinical Data from DUR-928 Phase 1b Trial in NASH and Phase 1 Trial in Hepatic...

CUPERTINO, Calif., June 23, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the presentation of additional clinical data from a DUR-928 Phase 1b trial in non-alcoholic steatohepat...

3 months ago - PRNewsWire

Best Penny Stocks To Buy Now? 7 To Watch This Week

What are the best penny stocks to buy this week? The post Best Penny Stocks To Buy Now?

Other symbols:AEZSAMRNGLBSLOTZMDWD
3 months ago - PennyStocks

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairm...

CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 International Liver Conference (EASL)  to be held virtually June...

3 months ago - PRNewsWire

Durect (DRRX) Reports Q1 Loss, Lags Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of 0.00% and -15.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Durect: Q1 Earnings Insights

Shares of Durect (NASDAQ:DRRX) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were unchanged 0.00% year over year to ($0.05), which missed ...

4 months ago - Benzinga

DURECT Corporation Announces First Quarter 2021 Financial Results and Update of Programs

CUPERTINO, Calif., May 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2021 and provided a corporate update.

4 months ago - PRNewsWire

Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now

Reddit penny stocks to watch as May 2021 gets kicked off The post Best Penny Stocks To Buy In May 2021? Take A Look At These Right Now appeared first on Penny Stocks to Buy, Picks, News and Information ...

Other symbols:ATOSSOS
4 months ago - PennyStocks

DURECT Corporation to Announce First Quarter 2021 Financial Results and Provide Business Update on May 4

CUPERTINO, Calif., April 27, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2021 financial results and host a conference call after the mark...

4 months ago - PRNewsWire

DURECT Corporation Announces Publication of DUR-928's Mechanism of Action

CUPERTINO, Calif., March 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed research paper describing the binding sites and proposed mechanism o...

6 months ago - PRNewsWire

Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of -33.33% and -66.91%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Durect: Q4 Earnings Insights

Shares of Durect (NASDAQ:DRRX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 100.00% year over year to ($0.04), which missed the estimate ...

6 months ago - Benzinga

DURECT Corporation Announces Fourth Quarter and Full Year 2020 Financial Results and Update of Programs

CUPERTINO, Calif., March 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months and year ended December 31, 2020 and provided a corporate update...

6 months ago - PRNewsWire

DURECT Corporation to Participate in Three Investor Conferences in March 2021

CUPERTINO, Calif., March 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that it will partipate in three upcoming investor conferences, taking place in March 2021. All conferen...

6 months ago - PRNewsWire

DURECT Corporation Announces Pricing of $42.5 Million Public Offering of Common Stock

CUPERTINO, Calif., Feb. 4, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver ...

7 months ago - PRNewsWire

DURECT Corporation Announces Proposed Offering of Common Stock

CUPERTINO, Calif., Feb. 3, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) ("DURECT"), a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver ...

7 months ago - PRNewsWire

Durect stock soars 34% after it gets FDA approval for surgical pain treatment

Shares of Durect Corp. gained 34.3% in premarket trading on Tuesday after the company said its drug, Posimer, had been approved by the Food and Drug Administration as a treatment for pain after a certai...

7 months ago - Market Watch

DURECT Corporation Announces U.S. FDA Approval of POSIMIR® For Post-Surgical Pain Reduction for up to 72 Hours Follow...

CUPERTINO, Calif., Feb. 2, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that the U.S. Food and Drug Administration (FDA) has approved POSIMIR® (bupivacaine solution) for infilt...

7 months ago - PRNewsWire